65 related articles for article (PubMed ID: 23863673)
1. [Hematologic adverse effects in patients with renal cell carcinoma treated with sunitinib].
Hong YP; Yao XD; Zhu Y; Zhang SL; Dai B; Zhang HL; Shen YJ; Zhu YP; Ma CG; Xiao WJ; Qin XJ; Lin GW; Ye DW
Zhonghua Yi Xue Za Zhi; 2013 Mar; 93(12):902-5. PubMed ID: 23863673
[TBL] [Abstract][Full Text] [Related]
2. Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.
Rautiola J; Utriainen T; Peltola K; Joensuu H; Bono P
Acta Oncol; 2014 Jan; 53(1):113-8. PubMed ID: 23721300
[TBL] [Abstract][Full Text] [Related]
3. [Exploratory analysis of the effect of toxicity of sunitinib on the clinical outcome of patients with advanced renal cell carcinoma].
Hong YP; Yao XD; Zhu Y; Ye DW; Shi GH; Zhang SL; Dai B; Zhang HL; Shen YJ; Zhu YP; Ma CG; Xiao WJ; Qin XJ; Lin GW
Zhonghua Yi Xue Za Zhi; 2013 Sep; 93(36):2880-3. PubMed ID: 24373400
[TBL] [Abstract][Full Text] [Related]
4. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma.
Najjar YG; Mittal K; Elson P; Wood L; Garcia JA; Dreicer R; Rini BI
Eur J Cancer; 2014 Apr; 50(6):1084-9. PubMed ID: 24559686
[TBL] [Abstract][Full Text] [Related]
5. Leukopenia as a biomarker of sunitinib outcome in advanced renal cell carcinoma.
Fujita T; Wakatabe Y; Matsumoto K; Tabata K; Yoshida K; Iwamura M
Anticancer Res; 2014 Jul; 34(7):3781-7. PubMed ID: 24982402
[TBL] [Abstract][Full Text] [Related]
6. C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib.
Fujita T; Iwamura M; Ishii D; Tabata K; Matsumoto K; Yoshida K; Baba S
Int J Urol; 2012 Oct; 19(10):908-13. PubMed ID: 22671963
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study.
Paglino C; Imarisio I; Ganini C; Morbini P; Vercelli A; Bregant C; Porta C
Future Oncol; 2012 Dec; 8(12):1605-12. PubMed ID: 23231522
[TBL] [Abstract][Full Text] [Related]
8. [Clinical study of Sunitinib in the treatment of metastatic renal clear cell carcinoma: a single center 23 cases experience].
Li XS; Song Y; Gong K; Zhang Q; Yu W; Song G; Zhao Z; Zhang Z; Wang G; Zhou LQ; He ZS; Jin J
Zhonghua Wai Ke Za Zhi; 2010 Mar; 48(5):375-7. PubMed ID: 20450612
[TBL] [Abstract][Full Text] [Related]
9. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
10. Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer.
De Giorgi U; Rihawi K; Aieta M; Lo Re G; Sava T; Masini C; Baldazzi V; De Vincenzo F; Camerini A; Fornarini G; Burattini L; Rosti G; Moscetti L; Chiuri VE; Luzi Fedeli S; Ferrari V; Scarpi E; Amadori D; Basso U
J Geriatr Oncol; 2014 Apr; 5(2):156-63. PubMed ID: 24495699
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib in metastatic renal cell carcinoma patients with brain metastases.
Gore ME; Hariharan S; Porta C; Bracarda S; Hawkins R; Bjarnason GA; Oudard S; Lee SH; Carteni G; Nieto A; Yuan J; Szczylik C
Cancer; 2011 Feb; 117(3):501-9. PubMed ID: 20862748
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of a low-dose, 2-week administration of sunitinib followed by a week rest (2/1 schedule) for metastatic renal cell carcinoma: a single center experience of six cases.
Makino K; Yoda K; Tomoishi J; Kume H
BMC Res Notes; 2014 Dec; 7():872. PubMed ID: 25471941
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of sunitinib in patients with metastatic renal cell carcinoma: initial experience in two Chinese centers.
He Z; Guo G; Zhang C; Li X; Fu W; Jin J; Zhang X; Zhou L
Chin Med J (Engl); 2014; 127(8):1450-3. PubMed ID: 24762587
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.
Josephs D; Hutson TE; Cowey CL; Pickering LM; Larkin JM; Gore ME; Van Hemelrijck M; McDermott DF; Powles T; Chowdhury P; Karapetis C; Harper PG; Choueiri TK; Chowdhury S
BJU Int; 2011 Oct; 108(8):1279-83. PubMed ID: 21244613
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency.
Kim KH; Kim HY; Kim HR; Sun JM; Lim HY; Lee HJ; Lee S; Bae WK; Rha SY; ;
Eur J Cancer; 2014 Mar; 50(4):746-52. PubMed ID: 24332573
[TBL] [Abstract][Full Text] [Related]
16. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
Tsimafeyeu I; Zart JS; Chung B
BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.
Sternberg CN; Calabrò F; Bracarda S; Cartenì G; Lo Re G; Ruggeri EM; Basso U; Gasparini G; Ciuffreda L; Ferrari V; Bonetti A; Fea E; Gasparro D; Tassinari D; Labianca R; Masini C; Fly K; Zhang K; Hariharan S; Capaccetti B; Porta C
Oncology; 2015; 88(5):273-80. PubMed ID: 25592399
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma.
Motzer RJ; Hutson TE; Olsen MR; Hudes GR; Burke JM; Edenfield WJ; Wilding G; Agarwal N; Thompson JA; Cella D; Bello A; Korytowsky B; Yuan J; Valota O; Martell B; Hariharan S; Figlin RA
J Clin Oncol; 2012 Apr; 30(12):1371-7. PubMed ID: 22430274
[TBL] [Abstract][Full Text] [Related]
20. Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature.
Bjarnason GA; Khalil B; Hudson JM; Williams R; Milot LM; Atri M; Kiss A; Burns PN
Urol Oncol; 2014 May; 32(4):480-7. PubMed ID: 24321258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
